WGI-0301 with nivolumab for advanced liver or kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an experimental drug (WGI-0301) combined with an FDA-approved immunotherapy drug (nivolumab, also known as Opdivo) for advanced liver or kidney cancer. The goal is to see if this combination is safe and effective for patients whose cancer has either not responded to standard treatment or has not been treated yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have either advanced liver cancer (HCC) that has progressed after first-line treatment, or advanced kidney cancer (RCC) that has not been treated or has progressed after first-line therapy.
- Your liver function is adequate (Child-Pugh Class A or B score ≤7).
- You are able to perform daily activities with some help (ECOG score 0 or 1).
- You must have at least one measurable tumor that has not been treated with local therapy, or a new area of progression.
- You must have adequate blood counts and organ function, and you cannot have major bleeding risks or severe autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, WGI-0301, for people with advanced hepatocellular carcinoma (HCC, a type of liver cancer) that has progressed after standard treatments. It aims to see if WGI-0301 can help control the cancer when other options have stopped working or caused side effects.
This trial tests a new drug (WGI-0301) combined with an existing liver cancer medicine (lenvatinib). It aims to see if the combination can help people with advanced liver cancer when other treatments haven't worked.
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
This study tests an experimental drug (HC-7366) combined with standard immunotherapy for advanced kidney cancer. It aims to see if this combo can help control the cancer better, and checks safety and effectiveness.
This trial tests a new drug, BMS-986527, for people with advanced kidney cancer that has not responded to standard treatments. The goal is to see if it is safe and if it helps shrink tumors.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.